A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Recruiting in Palo Alto (17 mi)
+5 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Seagen Inc.
No Placebo Group
Prior Safety Data
Breakthrough Therapy
Approved in 2 Jurisdictions
Trial Summary
What is the purpose of this trial?
This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.
Research Team
RS
Robert Sims, MD
Principal Investigator
Seagen Inc.
Eligibility Criteria
Inclusion Criteria
Treatment-naive patients with CD30-expressing PTCL (Part F)
Ineligible for or have declined initial conventional combination chemotherapy for HL (Parts A, B, C, and D)
See 9 more
Exclusion Criteria
Symptomatic neurologic disease compromising IADLs or requiring medication
History of progressive multifocal leukoencephalopathy
Grade 3 or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of brentuximab vedotin
See 5 more
Treatment Details
Interventions
- Brentuximab Vedotin (Monoclonal Antibodies)
Participant Groups
6Treatment groups
Experimental Treatment
Group I: Part F: Brentuximab Vedotin in PTCL PatientsExperimental Treatment1 Intervention
Group II: Part E: Brentuximab Vedotin in HL PatientsExperimental Treatment1 Intervention
Group III: Part D: Brentuximab Vedotin + Nivolumab in HL PatientsExperimental Treatment2 Interventions
Group IV: Part C: Brentuximab Vedotin + Bendamustine in HL PatientsExperimental Treatment2 Interventions
Group V: Part B: Brentuximab Vedotin + Dacarbazine in HL PatientsExperimental Treatment2 Interventions
Group VI: Part A: Brentuximab Vedotin in HL PatientsExperimental Treatment1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Virginia Cancer Specialists, PCFairfax, VA
Shenandoah Oncology P.C.Winchester, VA
Columbia University Medical CenterNew York, NY
City of Hope National Medical CenterDuarte, CA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Seagen Inc.
Lead Sponsor
Trials
212
Patients Recruited
73,800+
Founded
1997
Headquarters
Bothell, USA
Known For
Antibody-Drug Conjugates
Top Products
Adcetris (brentuximab vedotin), Tukysa (tucatinib), Padcev (enfortumab vedotin-ejfv), Tivdak (tisotumab vedotin-tftv)
Bristol-Myers Squibb
Industry Sponsor
Trials
2731
Patients Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia